Newsroom | 20131 results

Sorted by: Latest
Genetics
-

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands...
-

Beyond Cellular Models: Longevica Capitalizes on World’s Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline

SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--Longevica forms a star SAB to turn its $13M, 16k-subject mammalian study into AI-driven drug discovery, pet health, and novel human therapies....
-

VB Spine Announces FDA Breakthrough Device Designation for New Blood Test Designed to Identify Patients at Risk for Scoliosis Progression

NEW YORK--(BUSINESS WIRE)--VB Spine has received FDA Breakthrough Device Designation for a new blood test designed to identify patients at risk for scoliosis progression....
-

Amorepacific and Junevity Partner to Develop Next-Generation Products for Skin Rejuvenation

SAN FRANCISCO & SEOUL, South Korea--(BUSINESS WIRE)--Amorepacific and Junevity Partner to Develop Next-Generation Products for Skin Rejuvenation...
-

TECPR2 Research Foundation and Forge Biologics Announce AAV Development and Manufacturing Partnership to Advance Gene Therapy for TECPR2

BOCA RATON, Fla. & COLUMBUS, Ohio--(BUSINESS WIRE)--The TECPR2 Research Foundation, a nonprofit organization established to advance research and development of a treatment for patients with TECPR2, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to advance an AAV gene therapy for patients with TECPR2, an ultra-rare neurodegenerative genetic disease. Under the partners...
-

Secretome Therapeutics Announces Initiation of THRIVE-2 Phase 2 Clinical Study Evaluating STM-01 in Duchenne Muscular Dystrophy

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the initiation of THRIVE-2, a Phase 2 clinical study evaluating STM-01 in patients with Duchenne muscular dystrophy (DMD). The study is now open for enrollment, with the first patient expected to enroll imminently. THRIVE-2 is a multicenter, multi-dose, open-label Phase 2 study designed to evaluate the saf...
-

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs...
-

VectorY Expands PIONEER-ALS Phase 1/2 Clinical Trial Size

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics announces the expansion of its ongoing Phase 1/2 PIONEER-ALS® clinical trial of VTx-002 from 12 to 36 participants in ALS....
-

Promega Launches Paradyme™ 27GY STR System, Minimizing Stutter Artifacts in Forensic DNA Analysis

MADISON, Wis.--(BUSINESS WIRE)--Promega launches Paradyme™ 27GY STR System, the first STR kit with Reduced-Stutter Polymerase for faster, more confident mixture analysis....
-

Institute for Protein Innovation Appoints Kevin J. Harvey, Ph.D., as President and Chief Executive Officer

BOSTON--(BUSINESS WIRE)--The Institute for Protein Innovation (IPI), a nonprofit research organization advancing protein science to accelerate biomedical research and improve human health, today announced the appointment of Kevin J. Harvey, Ph.D., as President and Chief Executive Officer. Dr. Harvey joins IPI from Aviva Systems Biology, bringing more than two decades of leadership and research experience focused on antibodies, protein research, and life science research tools. The IPI Board bel...